



PRESS RELEASE

CAPLIN STERILES GETS USFDA APPROVAL FOR ROPIVACAINE HYDROCHLORIDE INJECTION USP

Chennai, April 13, 2020: Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT) Caplin Steriles Limited, a Subsidiary Company of Caplin Point Laboratories Limited, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ropivacaine Hydrochloride injection USP, 0.2 % in 40 mg/20 mL (2 mg/mL), 0.5 % in 100 mg/20 mL (5 mg/mL), 0.5 % in 150 mg/30 mL (5 mg/mL) and 1 % in 200 mg/20 mL (10 mg/mL) Single-dose vial presentations, a generic therapeutic equivalent version of (RLD), NAROPIN Injection, of Fresenius Kabi USA LLC. According to IQVIA™ (IMS Health), Ropivacaine Hydrochloride injection USP had US sales data of approximately \$34 million for the 12-month period ending Dec 2019. Caplin Steriles Limited, has developed and filed 16 ANDAs on its own and with partners, with 8 approvals so far.

Ropivacaine Hydrochloride is a long acting local anesthetic drug used for surgery or acute pain management.

Mr.C.C.Paarthipan, Chairman of Caplin Point Laboratories Limited commented “We’re glad to receive this approval, particularly as this product has been frequently on the shortage list in the US in recent times. We would be launching this product shortly, and hope to alleviate some of the shortages.”

The Company is also working on a portfolio of 35 simple and complex Injectable and Ophthalmic products, to be filed over the next 4 years.

ABOUT CAPLIN POINT LABORATORIES LIMITED:

Caplin Point Laboratories Limited is a fast-growing pharmaceutical Company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company’s Subsidiary Caplin Steriles Limited caters to the Regulated Markets for Injectable and Ophthalmic products.

Caplin Point Laboratories Limited has been selected on Forbes Asia’s “200 Best Under a Billion” list for three consecutive years (2014, 2015 & 2016), and was recently awarded “The Emerging Company of 2018” and “Business Excellence Award for 2019” by Economic Times.



Cautionary Statement:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations Team at Caplin

Mr. Vinod Kumar (Company Secretary)

Tel: +91 44 24968000

investor@caplinpoint.net

Registered Office

Narbavi No. 3, Lakshmanan Street,

T Nagar, Chennai, Tamil Nadu, 600017

Telephone: 044-28156653

CIN: L24231TN1990PLC019053

ISIN: INE475E01026

NSE Scrip Symbol: CAPLIPOINT

BSE Scrip Code: 524742

Website: www.caplinpoint.net